[{"id":"cc6777a2-fbfc-48e1-b267-86384bf3d7ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03473925","created_at":"2021-01-18T17:07:13.286Z","updated_at":"2024-07-02T16:36:08.140Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)","source_id_and_acronym":"NCT03473925","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • navarixin (MK-7123)"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 04/10/2018","start_date":" 04/10/2018","primary_txt":" Primary completion: 05/19/2021","primary_completion_date":" 05/19/2021","study_txt":" Completion: 05/19/2021","study_completion_date":" 05/19/2021","last_update_posted":"2022-06-29"}]